Articles by Anas Younes, MD
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma
ByKaren M. Winkfield, MD, PhD,Ranjana H. Advani, MD,Leslie K. Ballas, MD,Bouthaina S. Dabaja, MD,Sughosh Dhakal, MD,Christopher R. Flowers, MD, MS,Chul Soo Ha, MD,Bradford S. Hoppe, MD, MPH,David B. Mansur, MD,Nancy P. Mendenhall, MD,Monika L. Metzger, MD,John P. Plastaras, MD, PhD,Kenneth B. Roberts, MD,Ronald Shapiro, MD,Sonali M. Smith, MD,Stephanie A. Terezakis, MD,Anas Younes, MD,Louis S. Constine, MD By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.
With the progress in diagnostic methods that has made it possible to decipher the genetic code of DLBCL within a relatively short time, and with the increasing number of drugs that are entering clinical trials, our next big challenge is to enroll patients in trials in a timely manner.
ACR Appropriateness Criteria® Localized Nodal Indolent Lymphoma
ByBradford S. Hoppe, MD, MPH,David C. Hodgson, MD,Ranjana H. Advani, MD,Bouthaina S. Dabaja, MD,Christopher R. Flowers, MD, MS,Chul Soo Ha, MD,Monika L. Metzger, MD,John P. Plastaras, MD, PhD,Kenneth B. Roberts, MD,Ronald Shapiro, MD,Stephanie A. Terezakis, MD,Karen M. Winkfield, MD, PhD,Anas Younes, MD,Louis S. Constine, MD The present guidelines review epidemiology, pathology, presentation, workup, staging, prognostic factors, and treatment options for patients with localized nodal indolent lymphoma, with an emphasis on radiation guidelines, including radiation dose, field design, and radiation techniques.
We presented an interactive session entitled “Using Social Media in Oncology for Education and Patient Engagement” at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting. This article summarizes the points made in those presentations.
Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphoma
ByAndreas H. Sarris, MD, PhD,Jorge Romaguera, MD,Fredrick B. Hagemeister, MD,Maria A. Rodriguez, MD,Peter Mclaughlin, MD,Barbara Pro, MD,Anas Younes, MD,Ofie Mesina, RN,Fernando Cabanillas, MD,L. Jeffrey Medeiros, MD,Barry Samuels, MD Irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity. Various schedules and doses have been studied, and major complications were delayed diarrhea and
